Ligand ID: MMZ


Drugbank ID:
DB00763
(Methimazole)


Indication:
For the treatment of hyperthyroidism, goiter, Graves disease and psoriasis.

Get human targets for MMZ in PDB (known and potential targets)

RESULTS FROM SUB-STRUCTURAL SIMILARITY SEARCHES MAPPED TO LIGAND 'MMZ' AND SARS-COV-2 / COVID-19 STRUCTURES

1) User may click on the DrReposER ID (the first column) to get information on the binding sites and drug molecule.
2) Click View (the second last column) to view matched residues and superposition in the NGL viewer (upper right part).
3) User may also click on the Dock (the last column) to get script for molecular docking in UCSF Chimera throuh AutoDock Vina.

DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 View Interface RMSD Seq.
Identity (%)		 HETATM Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_B_MMZB501_1
(MONOOXYGENASE)		6lzg SPIKE GLYCOPROTEIN
(SARS-CoV-2)		3 / 3
ASN B 440
TYR B 508
SER B 443
1.17A18.58
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5GSN_A_MMZA503_1
(FLAVIN-CONTAINING
MONOOXYGENASE)		6m2n 3CL PROTEASE
(SARS-CoV-2)		3 / 3
ASN B 214
SER B   1
SER D 139
1.70A20.26
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_B_MMZB501_1
(MONOOXYGENASE)		6m3m NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		3 / 3
ASN A  78
TYR A 113
SER A  80
1.49A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5GSN_A_MMZA503_1
(FLAVIN-CONTAINING
MONOOXYGENASE)		6m71 NSP12
(SARS-CoV-2)		3 / 3
ASN A 360
SER A 363
SER A 364
1.34A18.46
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5GSN_A_MMZA503_1
(FLAVIN-CONTAINING
MONOOXYGENASE)		6m71 NSP12
(SARS-CoV-2)		3 / 3
ASN A 874
SER A 434
SER A 433
1.75A18.46
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_B_MMZB501_1
(MONOOXYGENASE)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		3 / 3
ASN A 440
TYR A 508
SER A 443
1.24A16.46
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_B_MMZB501_1
(MONOOXYGENASE)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		3 / 3
ASN A 440
TYR A 508
SER A 443
1.10A16.18
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_B_MMZB501_1
(MONOOXYGENASE)		6w4h SARS-COV-2 NSP16
(SARS-CoV-2)		3 / 3
ASN A6941
TYR A6979
SER A6943
1.38A20.13
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_B_MMZB501_1
(MONOOXYGENASE)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		3 / 3
ASN A6941
TYR A6979
SER A6943
1.40A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_E_MMZE501_1
(MONOOXYGENASE)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		3 / 3
ASN A6996
TYR A6930
SER A7000
1.68A
None
KCX  A6935 ( 4.7A)
KCX  A6935 ( 3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_E_MMZE501_1
(MONOOXYGENASE)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		3 / 3
ASN A6941
TYR A6979
SER A6973
1.76A
None
None
EDO  A7102 ( 4.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_E_MMZE501_1
(MONOOXYGENASE)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		3 / 3
ASN A6941
TYR A6979
SER A6943
1.42A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_B_MMZB501_1
(MONOOXYGENASE)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		3 / 3
ASN A6996
TYR A6930
SER A7000
1.66A
None
KCX  A6935 ( 4.7A)
KCX  A6935 ( 3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_B_MMZB501_1
(MONOOXYGENASE)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		3 / 3
ASN A6941
TYR A6979
SER A6973
1.74A
None
None
EDO  A7102 ( 4.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_B_MMZB501_1
(MONOOXYGENASE)		6w75 NSP16
(SARS-CoV-2)		3 / 3
ASN A6996
TYR A6828
SER A7000
1.07A17.37
FMT  A7104 ( 3.3A)
None
FMT  A7105 ( 2.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_E_MMZE501_1
(MONOOXYGENASE)		6w75 NSP16
(SARS-CoV-2)		3 / 3
ASN C6941
TYR C6979
SER C6943
1.37A17.37
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_B_MMZB501_1
(MONOOXYGENASE)		6w75 NSP16
(SARS-CoV-2)		3 / 3
ASN A6941
TYR A6979
SER A6973
1.74A17.37
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_B_MMZB501_1
(MONOOXYGENASE)		6w75 NSP16
(SARS-CoV-2)		3 / 3
ASN C6996
TYR C6930
SER C7000
1.66A17.37
FMT  C7108 ( 3.4A)
FMT  C7107 ( 4.3A)
FMT  C7110 ( 2.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_B_MMZB501_1
(MONOOXYGENASE)		6w75 NSP16
(SARS-CoV-2)		3 / 3
ASN C6941
TYR C6979
SER C6973
1.73A17.37
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_B_MMZB501_1
(MONOOXYGENASE)		6w75 NSP16
(SARS-CoV-2)		3 / 3
ASN C6941
TYR C6979
SER C6943
1.35A17.37
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_E_MMZE501_1
(MONOOXYGENASE)		6w75 NSP16
(SARS-CoV-2)		3 / 3
ASN A6996
TYR A6828
SER A7000
1.06A17.37
FMT  A7104 ( 3.3A)
None
FMT  A7105 ( 2.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_B_MMZB501_1
(MONOOXYGENASE)		6w75 NSP16
(SARS-CoV-2)		3 / 3
ASN A6941
TYR A6979
SER A6943
1.35A17.37
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_B_MMZB501_1
(MONOOXYGENASE)		6w75 NSP16
(SARS-CoV-2)		3 / 3
ASN C6996
TYR C6828
SER C7000
0.98A17.37
FMT  C7108 ( 3.4A)
None
FMT  C7110 ( 2.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_E_MMZE501_1
(MONOOXYGENASE)		6w75 NSP16
(SARS-CoV-2)		3 / 3
ASN A6941
TYR A6979
SER A6973
1.75A17.37
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_E_MMZE501_1
(MONOOXYGENASE)		6w75 NSP16
(SARS-CoV-2)		3 / 3
ASN A6996
TYR A6930
SER A7000
1.69A17.37
FMT  A7104 ( 3.3A)
FMT  A7103 ( 4.4A)
FMT  A7105 ( 2.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_E_MMZE501_1
(MONOOXYGENASE)		6w75 NSP16
(SARS-CoV-2)		3 / 3
ASN A6941
TYR A6979
SER A6943
1.36A17.37
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_E_MMZE501_1
(MONOOXYGENASE)		6w75 NSP16
(SARS-CoV-2)		3 / 3
ASN C6996
TYR C6930
SER C7000
1.68A17.37
FMT  C7108 ( 3.4A)
FMT  C7107 ( 4.3A)
FMT  C7110 ( 2.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_E_MMZE501_1
(MONOOXYGENASE)		6w75 NSP16
(SARS-CoV-2)		3 / 3
ASN C6996
TYR C6828
SER C7000
0.98A17.37
FMT  C7108 ( 3.4A)
None
FMT  C7110 ( 2.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_B_MMZB501_1
(MONOOXYGENASE)		6w75 NSP16
(SARS-CoV-2)		3 / 3
ASN A6996
TYR A6930
SER A7000
1.68A17.37
FMT  A7104 ( 3.3A)
FMT  A7103 ( 4.4A)
FMT  A7105 ( 2.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_E_MMZE501_1
(MONOOXYGENASE)		6w75 NSP16
(SARS-CoV-2)		3 / 3
ASN C6941
TYR C6979
SER C6973
1.75A17.37
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_B_MMZB501_1
(MONOOXYGENASE)		6wiq NSP7
NSP8
(SARS-CoV-2)		3 / 3
ASN B 118
TYR B 149
SER A  57
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_E_MMZE501_1
(MONOOXYGENASE)		6wiq NSP7
NSP8
(SARS-CoV-2)		3 / 3
ASN B 118
TYR B 149
SER A  57
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_E_MMZE501_1
(MONOOXYGENASE)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		3 / 3
ASN A6941
TYR A6979
SER A6973
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_E_MMZE501_1
(MONOOXYGENASE)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		3 / 3
ASN C6996
TYR C6930
SER C7000
1.69A
None
FMT  C7104 ( 4.2A)
FMT  C7104 ( 3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_E_MMZE501_1
(MONOOXYGENASE)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		3 / 3
ASN A6996
TYR A6828
SER A7000
1.05A
None
None
FMT  A7104 ( 2.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_E_MMZE501_1
(MONOOXYGENASE)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		3 / 3
ASN C6941
TYR C6979
SER C6973
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_B_MMZB501_1
(MONOOXYGENASE)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		3 / 3
ASN C6941
TYR C6979
SER C6973
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_B_MMZB501_1
(MONOOXYGENASE)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		3 / 3
ASN A6996
TYR A6930
SER A7000
1.69A
None
FMT  A7103 ( 4.3A)
FMT  A7104 ( 2.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_E_MMZE501_1
(MONOOXYGENASE)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		3 / 3
ASN C6941
TYR C6979
SER C6943
1.37A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_B_MMZB501_1
(MONOOXYGENASE)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		3 / 3
ASN A6996
TYR A6828
SER A7000
1.05A
None
None
FMT  A7104 ( 2.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_E_MMZE501_1
(MONOOXYGENASE)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		3 / 3
ASN A6941
TYR A6979
SER A6943
1.37A
None
None
FMT  A7108 (-2.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_B_MMZB501_1
(MONOOXYGENASE)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		3 / 3
ASN A6941
TYR A6979
SER A6973
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_B_MMZB501_1
(MONOOXYGENASE)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		3 / 3
ASN C6996
TYR C6828
SER C7000
1.01A
None
None
FMT  C7104 ( 3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_E_MMZE501_1
(MONOOXYGENASE)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		3 / 3
ASN C6996
TYR C6828
SER C7000
1.00A
None
None
FMT  C7104 ( 3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_B_MMZB501_1
(MONOOXYGENASE)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		3 / 3
ASN A6941
TYR A6979
SER A6943
1.36A
None
None
FMT  A7108 (-2.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_B_MMZB501_1
(MONOOXYGENASE)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		3 / 3
ASN C6996
TYR C6930
SER C7000
1.68A
None
FMT  C7104 ( 4.2A)
FMT  C7104 ( 3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_E_MMZE501_1
(MONOOXYGENASE)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		3 / 3
ASN A6996
TYR A6930
SER A7000
1.71A
None
FMT  A7103 ( 4.3A)
FMT  A7104 ( 2.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_B_MMZB501_1
(MONOOXYGENASE)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		3 / 3
ASN C6941
TYR C6979
SER C6943
1.35A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_B_MMZB501_1
(MONOOXYGENASE)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		3 / 3
ASN A  77
TYR A 112
SER A  79
1.50A
None
None
ZN  A 201 (-3.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_E_MMZE501_1
(MONOOXYGENASE)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		3 / 3
ASN C  77
TYR C 112
SER C  79
1.50A
None
None
ZN  C 201 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_B_MMZB501_1
(MONOOXYGENASE)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		3 / 3
ASN C  77
TYR C 112
SER C  79
1.49A
None
None
ZN  C 201 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_E_MMZE501_1
(MONOOXYGENASE)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		3 / 3
ASN A  77
TYR A 112
SER A  79
1.52A
None
None
ZN  A 201 (-3.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_B_MMZB501_1
(MONOOXYGENASE)		6wkq NSP16
(SARS-CoV-2)		3 / 3
ASN A6941
TYR A6979
SER A6943
1.36A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_E_MMZE501_1
(MONOOXYGENASE)		6wkq NSP16
(SARS-CoV-2)		3 / 3
ASN C6996
TYR C6930
SER C7000
1.68A
None
FMT  C7104 ( 4.3A)
FMT  C7110 ( 3.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_B_MMZB501_1
(MONOOXYGENASE)		6wkq NSP16
(SARS-CoV-2)		3 / 3
ASN A6996
TYR A6930
SER A7000
1.69A
None
FMT  A7105 ( 4.4A)
FMT  A7106 ( 2.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_E_MMZE501_1
(MONOOXYGENASE)		6wkq NSP16
(SARS-CoV-2)		3 / 3
ASN C6941
TYR C6979
SER C6973
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_B_MMZB501_1
(MONOOXYGENASE)		6wkq NSP16
(SARS-CoV-2)		3 / 3
ASN C6941
TYR C6979
SER C6973
1.73A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_E_MMZE501_1
(MONOOXYGENASE)		6wkq NSP16
(SARS-CoV-2)		3 / 3
ASN A6941
TYR A6979
SER A6973
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_E_MMZE501_1
(MONOOXYGENASE)		6wkq NSP16
(SARS-CoV-2)		3 / 3
ASN A6941
TYR A6979
SER A6943
1.37A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_E_MMZE501_1
(MONOOXYGENASE)		6wkq NSP16
(SARS-CoV-2)		3 / 3
ASN C6996
TYR C6828
SER C7000
1.00A
None
None
FMT  C7110 ( 3.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_B_MMZB501_1
(MONOOXYGENASE)		6wkq NSP16
(SARS-CoV-2)		3 / 3
ASN C6941
TYR C6979
SER C6943
1.36A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_B_MMZB501_1
(MONOOXYGENASE)		6wkq NSP16
(SARS-CoV-2)		3 / 3
ASN C6996
TYR C6930
SER C7000
1.66A
None
FMT  C7104 ( 4.3A)
FMT  C7110 ( 3.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_B_MMZB501_1
(MONOOXYGENASE)		6wkq NSP16
(SARS-CoV-2)		3 / 3
ASN C6996
TYR C6828
SER C7000
1.01A
None
None
FMT  C7110 ( 3.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_E_MMZE501_1
(MONOOXYGENASE)		6wkq NSP16
(SARS-CoV-2)		3 / 3
ASN C6941
TYR C6979
SER C6943
1.38A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_E_MMZE501_1
(MONOOXYGENASE)		6wkq NSP16
(SARS-CoV-2)		3 / 3
ASN A6996
TYR A6930
SER A7000
1.70A
None
FMT  A7105 ( 4.4A)
FMT  A7106 ( 2.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_B_MMZB501_1
(MONOOXYGENASE)		6wkq NSP16
(SARS-CoV-2)		3 / 3
ASN A6941
TYR A6979
SER A6973
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_B_MMZB501_1
(MONOOXYGENASE)		6wkq NSP16
(SARS-CoV-2)		3 / 3
ASN A6996
TYR A6828
SER A7000
1.05A
None
None
FMT  A7106 ( 2.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_B_MMZB501_1
(MONOOXYGENASE)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		3 / 3
ASN A6941
TYR A6979
SER A6943
1.36A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_B_MMZB501_1
(MONOOXYGENASE)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		3 / 3
ASN A6941
TYR A6979
SER A6973
1.73A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_E_MMZE501_1
(MONOOXYGENASE)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		3 / 3
ASN A6941
TYR A6979
SER A6973
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_E_MMZE501_1
(MONOOXYGENASE)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		3 / 3
ASN A6941
TYR A6979
SER A6943
1.38A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_B_MMZB501_1
(MONOOXYGENASE)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		3 / 3
ASN A6996
TYR A6930
SER A7000
1.73A
GTA  A7102 (-3.9A)
GTA  A7102 ( 3.9A)
GTA  A7102 (-2.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_E_MMZE501_1
(MONOOXYGENASE)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		3 / 3
ASN A6996
TYR A6930
SER A7000
1.74A
GTA  A7102 (-3.9A)
GTA  A7102 ( 3.9A)
GTA  A7102 (-2.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_E_MMZE501_1
(MONOOXYGENASE)		6wqd NSP7
NSP8
(SARS-CoV-2)		3 / 3
ASN D 118
TYR D 149
SER C  57
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_E_MMZE501_1
(MONOOXYGENASE)		6wqd NSP7
NSP8
(SARS-CoV-2)		3 / 3
ASN B 118
TYR B 149
SER A  57
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_E_MMZE501_1
(MONOOXYGENASE)		6wqd NSP7
NSP8
(SARS-CoV-2)		3 / 3
ASN D 118
TYR D 149
SER C  54
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_B_MMZB501_1
(MONOOXYGENASE)		6wqd NSP7
NSP8
(SARS-CoV-2)		3 / 3
ASN D 118
TYR D 149
SER C  54
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_B_MMZB501_1
(MONOOXYGENASE)		6wqd NSP7
NSP8
(SARS-CoV-2)		3 / 3
ASN B 118
TYR B 149
SER A  54
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_E_MMZE501_1
(MONOOXYGENASE)		6wqd NSP7
NSP8
(SARS-CoV-2)		3 / 3
ASN B 118
TYR B 149
SER A  54
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_E_MMZE501_1
(MONOOXYGENASE)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		3 / 3
ASN B 118
TYR B 149
SER A  54
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_E_MMZE501_1
(MONOOXYGENASE)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		3 / 3
ASN B 118
TYR B 149
SER A  57
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_E_MMZE501_1
(MONOOXYGENASE)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		3 / 3
ASN D 118
TYR D 149
SER C  54
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_B_MMZB501_1
(MONOOXYGENASE)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		3 / 3
ASN D 118
TYR D 149
SER C  54
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_B_MMZB501_1
(MONOOXYGENASE)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		3 / 3
ASN B 118
TYR B 149
SER A  57
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_B_MMZB501_1
(MONOOXYGENASE)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		3 / 3
ASN B 118
TYR B 149
SER A  54
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_E_MMZE501_1
(MONOOXYGENASE)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		3 / 3
ASN A 440
TYR A 508
SER A 443
1.06A
None
DMS  A 903 (-3.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_E_MMZE501_1
(MONOOXYGENASE)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		3 / 3
ASN E 440
TYR E 508
SER E 443
1.17A
None
DMS  E 902 (-4.0A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_B_MMZB501_1
(MONOOXYGENASE)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		3 / 3
ASN E 440
TYR E 508
SER E 443
1.23A
None
DMS  E 902 (-4.0A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_B_MMZB501_1
(MONOOXYGENASE)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		3 / 3
ASN A 440
TYR A 508
SER A 443
1.12A
None
DMS  A 903 (-3.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_B_MMZB501_1
(MONOOXYGENASE)		6ym0 LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		3 / 3
ASN E 388
TYR L  55
SER E 383
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_E_MMZE501_1
(MONOOXYGENASE)		6ym0 LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		3 / 3
ASN E 388
TYR L  55
SER E 383
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_B_MMZB501_1
(MONOOXYGENASE)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		3 / 3
ASN E 440
TYR E 508
SER E 443
1.24A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_E_MMZE501_1
(MONOOXYGENASE)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		3 / 3
ASN E 440
TYR E 508
SER E 443
1.17A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_E_MMZE501_1
(MONOOXYGENASE)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		3 / 3
ASN A 440
TYR A 508
SER A 443
1.17A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_B_MMZB501_1
(MONOOXYGENASE)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		3 / 3
ASN A 440
TYR A 508
SER A 443
1.23A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_B_MMZB501_1
(MONOOXYGENASE)		7btf NSP12
(SARS-CoV-2)		3 / 3
ASN A 703
TYR A 479
SER A 754
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_E_MMZE501_1
(MONOOXYGENASE)		7btf NSP12
(SARS-CoV-2)		3 / 3
ASN A 703
TYR A 479
SER A 754
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5GSN_A_MMZA503_1
(FLAVIN-CONTAINING
MONOOXYGENASE)		7btf NSP12
(SARS-CoV-2)		3 / 3
ASN A 568
SER A 564
SER A 561
1.76A18.46
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5GSN_A_MMZA503_1
(FLAVIN-CONTAINING
MONOOXYGENASE)		7bv1 NSP12
(SARS-CoV-2)		3 / 3
ASN A 874
SER A 434
SER A 433
1.25A18.70
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_B_MMZB501_1
(MONOOXYGENASE)		7bv1 NSP12
(SARS-CoV-2)		3 / 3
ASN A 703
TYR A 479
SER A 754
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_E_MMZE501_1
(MONOOXYGENASE)		7bv1 NSP12
(SARS-CoV-2)		3 / 3
ASN A 703
TYR A 479
SER A 754
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_E_MMZE501_1
(MONOOXYGENASE)		7bv2 NSP12
(SARS-CoV-2)		3 / 3
ASN A 703
TYR A 479
SER A 754
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GVC_B_MMZB501_1
(MONOOXYGENASE)		7bv2 NSP12
(SARS-CoV-2)		3 / 3
ASN A 703
TYR A 479
SER A 754
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5GSN_A_MMZA503_1
(FLAVIN-CONTAINING
MONOOXYGENASE)		7bv2 NSP12
(SARS-CoV-2)		3 / 3
ASN A 360
SER A 363
SER A 364
1.71A18.70
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5GSN_A_MMZA503_1
(FLAVIN-CONTAINING
MONOOXYGENASE)		7bv2 NSP12
(SARS-CoV-2)		3 / 3
ASN A 874
SER A 434
SER A 433
1.61A18.70
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5GSN_A_MMZA503_1
(FLAVIN-CONTAINING
MONOOXYGENASE)		7bv2 NSP12
(SARS-CoV-2)		3 / 3
ASN A 568
SER A 564
SER A 561
1.68A18.70
None